Facultad de Farmacia, Universidad San Pablo CEU, CEU Universities, Madrid, Spain.
CAPES Foundation, Ministry of Education of Brazil, Brasília, DF, 70040-020, Brazil.
Parasit Vectors. 2018 Jan 22;11(1):50. doi: 10.1186/s13071-018-2639-5.
The use of contact lenses has increased in recent years as has the incidence of Dry Eye Syndrome, partly due to their use. Artificial tears are the most common treatment option. Since these changes can facilitate Acanthamoeba infection, the present study has been designed to evaluate the effect of three artificial tears treatments in the viability of Acanthamoeba genotype T4 trophozoites. Optava Fusion™, Oculotect®, and Artelac® Splash were selected due to their formulation.
Viability was assessed using two staining methods, Trypan Blue stain and CTC stain at different time intervals (2, 4, 6, 8 and 24 h). Trypan Blue viability was obtained by manual count with light microscopy while the CTC stain was determined using flow cytometry.
Trypan Blue staining results demonstrated a decrease in viability for Optava Fusion™ and Artelac® Splash during the first 4 h of incubation. After, this effect seems to lose strength. In the case of Oculotect®, complete cell death was observed after 2 h. Using flow cytometry analysis, Optava Fusion™ and Oculotect® exhibited the same effect observed with Trypan Blue staining. However, Artelac® Splash revealed decreasing cell respiratory activity after four hours, with no damage to the cell membrane.
The present study uses, for the first time, CTC stain analyzed by flow cytometry to establish Acanthamoeba viability demonstrating its usefulness and complementarity with the traditional stain, Trypan Blue. Artelac® Splash, with no preservatives, and Optava Fusion TM, with Purite®, have not shown any useful amoebicidal activity. On the contrary, promising results presented by Ocultect®, with BAK, open up a new possibility for Acanthamoeba keratitis prophylaxis and treatment although in vivo studies should be carried out.
近年来,隐形眼镜的使用越来越多,干眼症的发病率也有所上升,部分原因是它们的使用。人工泪液是最常见的治疗选择。由于这些变化可能促进棘阿米巴感染,因此本研究旨在评估三种人工泪液治疗方法对棘阿米巴基因型 T4滋养体活力的影响。选择 Optava Fusion™、Oculotect®和 Artelac® Splash 是因为它们的配方。
使用两种染色方法,即台盼蓝染色和 CTC 染色,在不同的时间间隔(2、4、6、8 和 24 小时)评估活力。用台盼蓝染色通过手动计数和相差显微镜获得活力,而 CTC 染色则通过流式细胞术测定。
台盼蓝染色结果表明,Optava Fusion™和 Artelac® Splash 在孵育的前 4 小时内活力下降。之后,这种效应似乎减弱了。在 Oculotect®的情况下,2 小时后观察到完全细胞死亡。使用流式细胞术分析,Optava Fusion™和 Oculotect®表现出与台盼蓝染色相同的效果。然而,Artelac® Splash 在四小时后显示出细胞呼吸活性降低,而细胞膜没有受损。
本研究首次使用流式细胞术分析 CTC 染色来建立棘阿米巴活力,证明了其在传统染色方法台盼蓝染色中的有用性和互补性。不含防腐剂的 Artelac®Splash 和含有 Purite®的 Optava Fusion TM 均未显示出任何有用的杀阿米巴活性。相反,含 BAK 的 Ocultect®显示出有希望的结果,为棘阿米巴角膜炎的预防和治疗开辟了新的可能性,尽管应该进行体内研究。